AstraZeneca reports that a phase III trial showed that Imfinzi (durvalumab) combined with platinum-based chemotherapy followed by Imfinzi plus Lynparza (olaparib) improved several key secondary efficacy endpoints in patients with recurrent/unresectable pMMR endometrial carcinoma compared to chemotherapy alone.

Additional secondary endpoints showed consistent results for pMMR patients treated with Lynparza and Imfinzi, demonstrating a 32% reduction in the risk of second progression or death (PFS2) for the combination versus the control arm.

Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca, commented: 'DUO-E results have shown that the addition of Imfinzi to chemotherapy offers improved outcomes for patients with advanced endometrial cancer'.

Copyright (c) 2024 All rights reserved.